After considering the feedback from consultation, the Appraisal Committee has prepared a Final Appraisal Determination (FAD) on alendronate, etidronate, risedronate, raloxifene and strontium ranelate for the primary prevention of osteoporotic fragility fractures in postmenopausal women and submitted it to the Institute.

The FAD has been sent to the formal consultees for this appraisal who commented on the economic model. They have 15 working days to consider whether they wish to appeal against it.

Please note that the appeal period for this appraisal will close at 5pm on 21 December 2009.